Tranylcypromine reduces herpes simplex virus 1 infection in mice

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2807-2815

  Yao, Hui Wen ^a   Lin, Pin Hung ^b   Shen, Fang Hsiu ^b   Perng, Guey Chuen ^b   Tung, Yuk Ying ^b   Hsu, Sheng Min ^b   Chen, Shun Hua ^a,b,c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b Institute of Education   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; THYMIDINE KINASE; TRANYLCYPROMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BLINDNESS; CONTROLLED STUDY; CORNEA; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; ENCEPHALITIS; FEMALE; GANGLION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; MUTANT; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; TRIGEMINAL NERVE; VIRUS LOAD; VIRUS REACTIVATION; WILD TYPE; ANIMAL; CELL LINE; CELL PROLIFERATION; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; FLOW CYTOMETRY; METABOLISM; PATHOGENICITY; REAL TIME POLYMERASE CHAIN REACTION; VERO CELL LINE; VIROLOGY;

ANIMALS; CELL LINE; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; FLOW CYTOMETRY; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; MICE; REAL-TIME POLYMERASE CHAIN REACTION; THYMIDINE KINASE; TRANYLCYPROMINE; VERO CELLS;

EID: 84898621445     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02617-13     Document Type: Article

References (53)

1. Casrouge A, Zhang SY, Eidenschenk C, Jouanguy E, Puel A, Yang K, Alcais A, Picard C, Mahfoufi N, Nicolas N, Lorenzo L, Plancoulaine S, Senechal B, Geissmann F, Tabeta K, Hoebe K, Du X, Miller RL, Heron B, Mignot C, de Villemeur TB, Lebon P, Dulac O, Rozenberg F, Beutler B, Tardieu M, Abel L, Casanova JL. 2006. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 314:308-312. http://dx.doi.org/10.1126/science.1128346.
2. Corey L, Whitley RJ, Stone EF, Mohan K. 1988. Difference between herpes simplex virus type 1 and type 2 neonatal encephalitis in neurological outcome. Lancet i:1-4.
3. Roizman B, Knipe DM, Whitley RJ. 2007. Herpes simplex viruses, p 2501-2601. In Knipe DM, Howley PM (ed), Fields virology, 5th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.
4. Smith JS, Robinson NJ. 2002. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J. Infect. Dis. 186(Suppl 1):S3-S28. http://dx.doi.org/10.1086/343739.
5. Standberry LR, Jorgensen DM, Nahmias AJ. 1997. Herpes simplex virus 1 and 2, p 419-454. In Evans AS, Kaslow RA (ed), Viral infections of humans: epidemiology and control. Springer, New York, NY.
6. Whitley RJ. 1991. Herpes simplex virus infections of the central nervous system. Encephalitis and neonatal herpes. Drugs 42:406-427.
7. Biswas PS, Rouse BT. 2005. Early events in HSV keratitis-setting the stage for a blinding disease. Microbes Infect. 7:799-810. http://dx.doi.org/10. 1016/j.micinf.2005.03.003.
8. Liesegang TJ. 2001. Herpes simplex virus epidemiology and ocular importance. Cornea 20:1-13. http://dx.doi.org/10.1097/00003226-200101000-00001.
9. Pepose JS, Leib DA, Stuart PM, Easty EL. 1996. Herpes simplex virus disease: anterior segment of the eye, p 905-932. In Pepose JS, Holland GN, Wilhelmus KR (ed), Ocular infection and immunity. C.V. Mosby, St. Louis, MO.
10. Thomas J, Gangappa S, Kanangat S, Rouse BT. 1997. On the essential involvement of neutrophils in the immunopathologic disease: herpetic stromal keratitis. J. Immunol. 158:1383-1391.
11. Zheng M, Deshpande S, Lee S, Ferrara N, Rouse BT. 2001. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J. Virol. 75:9828-9835. http://dx.doi.org/10.1128/JVI.75.20.9828-9835.2001.
12. Herpetic Eye Disease Study Group. 2000. Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis. Arch. Ophthalmol. 118:1030-1036. http://dx.doi.org/10.1001/archopht. 118.8.1030.
13. Knickelbein JE, Hendricks RL, Charukamnoetkanok P. 2009. Management of herpes simplex virus stromal keratitis: an evidence-based review. Surv. Ophthalmol. 54:226-234. http://dx.doi.org/10.1016/j.survophthal.2008.12.004.
14. Naesens L, De Clercq E. 2001. Recent developments in herpesvirus therapy. Herpes 8:12-16.
15. Remeijer L, Osterhaus A, Verjans G. 2004. Human herpes simplex virus keratitis: the pathogenesis revisited. Ocul. Immunol. Inflamm. 12:255-285. http://dx.doi.org/10.1080/092739490500363.
16. Rezende RA, Bisol T, Hammersmith K, Rapuano CJ, Lima AL, Webster GF, Freitas JF, Laibson PR, Cohen EJ. 2006. Efficacy of oral antiviral prophylaxis in preventing ocular herpes simplex virus recurrences in patients with and without self-reported atopy. Am. J. Ophthalmol. 142:563-567. http://dx.doi.org/10.1016/j.ajo.2006.05.025.
17. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. 2003. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin. Microbiol. Rev. 16:114-128. http://dx.doi.org/10.1128/CMR.16.1. 114-128.2003.
18. Duan R, de Vries RD, Osterhaus AD, Remeijer L, Verjans GM. 2008. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J. Infect. Dis. 198:659-663. http://dx.doi.org/10.1086/590668.
19. Duan R, de Vries RD, van Dun JM, van Loenen FB, Osterhaus AD, Remeijer L, Verjans GM. 2009. Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis. J. Infect. Dis. 200:1402-1414. http://dx.doi.org/10.1086/606028.
20. Coen DM, Schaffer PA. 2003. Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat. Rev. Drug Discov. 2:278-288. http://dx.doi.org/10.1038/nrd1065.
21. Stranska R, van Loon AM, Polman M, Beersma MF, Bredius RG, Lankester AC, Meijer E, Schuurman R. 2004. Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients. Antivir. Ther. 9:565-575.
22. Knipe DM, Cliffe A. 2008. Chromatin control of herpes simplex virus lytic and latent infection. Nat. Rev. Microbiol. 6:211-221. http://dx.doi.org/10. 1038/nrmicro1794.
23. Kristie TM, Liang Y, Vogel JL. 2010. Control of alpha-herpesvirus IE gene expression by HCF-1 coupled chromatin modification activities. Biochim. Biophys. Acta 1799:257-265. http://dx.doi.org/10.1016/j.bbagrm.2009.08.003.
24. Liang Y, Vogel JL, Narayanan A, Peng H, Kristie TM. 2009. Inhibition of the histone demethylase LSD1 blocks alpha-herpesvirus lytic replication and reactivation from latency. Nat. Med. 15:1312-1317. http://dx.doi.org/10.1038/nm. 2051.
25. Liang Y, Vogel JL, Arbuckle JH, Rai G, Jadhav A, Simeonov A, Maloney DJ, Kristie TM. 2013. Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and reactivation from latency. Sci. Transl. Med. 5:167ra165. http://dx.doi.org/10.1126/scitranslmed.3005145.
26. Liang Y, Quenelle D, Vogel JL, Mascaro C, Ortega A, Kristie TM. 2013. A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. mBio 4:e00558-00512. http://dx.doi.org/10.1128/mBio.00558-12.
27. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, Gunther T, Buettner R, Schule R. 2005. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437:436-439. http://dx.doi.org/10.1038/nature04020.
28. Schmidt DM, McCafferty DG. 2007. Trans-2-phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 46:4408-4416. http://dx.doi.org/10.1021/bi0618621.
29. Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R. 2006. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem. Biol. 13:563-567. http://dx.doi.org/10.1016/j.chembiol.2006. 05.004.
30. Yang M, Culhane JC, Szewczuk LM, Jalili P, Ball HL, Machius M, Cole PA, Yu H. 2007. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. Biochemistry 46:8058-8065. http://dx.doi.org/10.1021/bi700664y.
31. Riederer P, Lachenmayer L, Laux G. 2004. Clinical applications of MAOinhibitors. Curr. Med. Chem. 11:2033-2043. http://dx.doi.org/10.2174/ 0929867043364775.
32. Thase ME, Trivedi MH, Rush AJ. 1995. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 12:185-219. http://dx.doi.org/10.1016/ 0893-133X(94)00058-8.
33. Youdim MB, Edmondson D, Tipton KF. 2006. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 7:295-309. http://dx.doi.org/10.1038/nrn1883.
34. Sacks SL, Wanklin RJ, Reece DE, Hicks KA, Tyler KL, Coen DM. 1989. Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? Ann. Intern. Med. 111:893-899.
35. Griffiths A, Chen SH, Horsburgh BC, Coen DM. 2003. Translational compensation of a frameshift mutation affecting herpes simplex virus thymidine kinase is sufficient to permit reactivation from latency. J. Virol. 77:4703-4709. http://dx.doi.org/10.1128/JVI.77.8.4703-4709.2003.
36. Chen SH, Yao HW, Chen IT, Shieh B, Li C, Chen SH. 2008. Suppression of transcription factor early growth response 1 reduces herpes simplex virus lethality in mice. J. Clin. Invest. 118:3470-3477. http://dx.doi.org/10.1172/ JCI35114.
37. Shen FH, Wang SW, Yeh TM, Tung YY, Hsu SM, Chen SH. 2013. Absence of CXCL10 aggravates herpes stromal keratitis with reduced primary neutrophil influx in mice. J. Virol. 87:8502-8510. http://dx.doi.org/10.1128/JVI.01198-13.
38. Davar G, Kramer MF, Garber D, Roca AL, Andersen JK, Bebrin W, Coen DM, Kosz-Vnenchak M, Knipe DM, Breakefield XO. 1994. Comparative efficacy of expression of genes delivered to mouse sensory neurons with herpes virus vectors. J. Comp. Neurol. 339:3-11. http://dx.doi.org/10.1002/cne.903390103.
39. Li ZH, Li CM, Ling P, Shen FH, Chen SH, Liu CC, Yu CK. 2008. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J. Infect. Dis. 197:854-857. http://dx.doi.org/10.1086/527326.
40. Yao HW, Chen SH, Li C, Tung YY, Chen SH. 2012. Suppression of transcription factor early growth response 1 reduces herpes simplex virus 1-induced corneal disease in mice. J. Virol. 86:8559-8567. http://dx.doi.org/10. 1128/JVI.00505-12.
41. Yao HW, Ling P, Chen SH, Tung YY, Chen SH. 2012. Factors affecting herpes simplex virus reactivation from the explanted mouse brain. Virology 433:116-123. http://dx.doi.org/10.1016/j.virol.2012.07.018.
42. Chen SH, Pearson A, Coen DM. 2004. Failure of thymidine kinasenegative herpes simplex virus to reactivate from latency following efficient establishment. J. Virol. 78:520-523. http://dx.doi.org/10.1128/JVI.78.1.520-523. 2004.
43. Biswas PS, Banerjee K, Kim B, Smith J, Rouse BT. 2005. A novel flow cytometry based assay for quantification of corneal angiogenesis in the mouse model of herpetic stromal keratitis. Exp. Eye Res. 80:73-81. http://dx.doi.org/10.1016/j.exer.2004.08.014.
44. Babu JS, Thomas J, Kanangat S, Morrison LA, Knipe DM, Rouse BT. 1996. Viral replication is required for induction of ocular immunopathology by herpes simplex virus. J. Virol. 70:101-107.
45. Sawtell NM, Thompson RL. 1992. Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J. Virol. 66:2150-2156.
46. Thompson RL, Preston CM, Sawtell NM. 2009. De novo synthesis of VP16 coordinates the exit from HSV latency in vivo. PLoS Pathog. 5:e1000352. http://dx.doi.org/10.1371/journal.ppat.1000352.
47. Lanteri C, Hernandez Vallejo SJ, Salomon L, Doucet EL, Godeheu G, Torrens Y, Houades V, Tassin JP. 2009. Inhibition of monoamine oxidases desensitizes 5-HT1A autoreceptors and allows nicotine to induce a neurochemical and behavioral sensitization. J. Neurosci. 29:987-997. http://dx.doi.org/10.1523/ JNEUROSCI.3315-08.2009.
48. Villegier AS, Salomon L, Blanc G, Godeheu G, Glowinski J, Tassin JP. 2006. Irreversible blockade of monoamine oxidases reveals the critical role of 5-HT transmission in locomotor response induced by nicotine in mice. Eur. J. Neurosci. 24:1359-1365. http://dx.doi.org/10.1111/j.1460-9568.2006.05011.x.
49. Thome J, Sakai N, Shin K, Steffen C, Zhang YJ, Impey S, Storm D, Duman RS. 2000. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J. Neurosci. 20:4030-4036.
50. Sun G, Alzayady K, Stewart R, Ye P, Yang S, Li W, Shi Y. 2010. Histone demethylase LSD1 regulates neural stem cell proliferation. Mol. Cell. Biol. 30:1997-2005. http://dx.doi.org/10.1128/MCB.01116-09.
51. Gilden DH, Mahalingam R, Cohrs RJ, Tyler KL. 2007. Herpesvirus infections of the nervous system. Nat. Clin. Pract. Neurol. 3:82-94. http://dx.doi.org/10. 1038/ncpneuro0401.
52. Christophers J, Clayton J, Craske J, Ward R, Collins P, Trowbridge M, Darby G. 1998. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob. Agents Chemother. 42:868-872.
53. Brand G, Schiavano GF, Balestra E, Tavazzi B, Perno CF, Magnani M. 2001. The potency of acyclovir can be markedly different in different cell types. Life Sci. 69:1285-1290. http://dx.doi.org/10.1016/S0024-3205(01) 01213-9.